Nice piece about how fares Roche’s huge phase III taspoglutide clinical programme - speculation that the end is nigh for the product....
http://seekingalpha.com/article/212478-roche-s-diabetes-dreams-fade-as-taspo-data-deteriorates
Analysts say that the chances of the drug reaching the market have fallen dramatically.
That's even tho they say it outperformed Lantus on glycaemic control, weight loss and hypoglycaemia, Januvia on glycaemic control and weight loss and glycaemic control against Byetta. But side effects may scupper things: initial tolerability and longer term hypersensitivity reactions.
8)
http://seekingalpha.com/article/212478-roche-s-diabetes-dreams-fade-as-taspo-data-deteriorates
Analysts say that the chances of the drug reaching the market have fallen dramatically.
That's even tho they say it outperformed Lantus on glycaemic control, weight loss and hypoglycaemia, Januvia on glycaemic control and weight loss and glycaemic control against Byetta. But side effects may scupper things: initial tolerability and longer term hypersensitivity reactions.
8)
